Propharma Consultants Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
as on 18-05-2024
- Paid Up Capital ₹ 0.10 M
as on 18-05-2024
- Company Age 3 Year, 4 Months
- Last Filing with ROC 31 Mar 2023
About Propharma Consultants
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Mrutunjay Mishra, Jitendra Singh, and Shushil Choubey serve as directors at the Company.
- CIN/LLPIN
U85100OR2021PTC037307
- Company No.
037307
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Aug 2021
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Cuttack
Industry
Company Details
- Location
Khorda, Odisha, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Propharma Consultants?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shushil Choubey  | Managing Director | 17-Aug-2021 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Mrutunjay Mishra | Director | 17-Aug-2021 | Current |
| Jitendra Singh | Director | 17-Aug-2021 | Current |
Financial Performance of Propharma Consultants.
Propharma Consultants Private Limited, for the financial year ended 2022, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Propharma Consultants?
Unlock access to Propharma Consultants's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Transintegra Biomedica Private LimitedActive 3 years 8 monthsJitendra Singh and Shushil Choubey are mutual person
- Jeevika Odisha Farmers Producer Company LimitedActive 2 years 14 days
Jitendra Singh is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Propharma Consultants?
Propharma Consultants has a workforce of 0 employees as of Mar 28, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Propharma Consultants, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Propharma Consultants's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
